Back to top
more

Zymeworks (ZYME)

(Delayed Data from NSDQ)

$15.61 USD

15.61
605,831

+0.95 (6.48%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $15.63 +0.02 (0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 23.40% and 44.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zymeworks (ZYME) Up on Licensing Deal With Jazz Pharmaceuticals

by Zacks Equity Research

Zymeworks (ZYME) inks a deal to license its lead candidate, zanidatamab, to Jazz Pharmaceuticals for the development and commercialization of the candidate in all territories except Asia-Pacific.

Denali Therapeutics Inc. (DNLI) Moves 17.7% Higher: Will This Strength Last?

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -4.30% and 34.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alimera Sciences (ALIM) delivered earnings and revenue surprises of 26.23% and 8.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks Inc. (ZYME) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -22.68% and 49.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks Inc. (ZYME) Surges 23.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Zymeworks Inc. (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zymeworks Inc. (ZYME) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 10.38% and 56.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Zymeworks Inc. (ZYME) Q4 Earnings Expected to Decline

by Zacks Equity Research

Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -5.75% and 139.40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks Inc. (ZYME) Soars 5.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Zymeworks Inc. (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Down 48.4% in 4 Weeks, Here's Why Zymeworks Inc. (ZYME) Looks Ripe for a Turnaround

by Zacks Equity Research

Zymeworks Inc. (ZYME) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Sanghamitra Saha headshot

Bank on Rising P/E Investing With These 5 Top-Ranked Stocks

by Sanghamitra Saha

Want to try a different approach? Tap five stocks with increasing P/E ratios such as MEDIFAST (MED), JAKKS Pacific (JAKK), Asbury Automotive Group (ABG), Zymeworks (ZYME) and Polaris (PII).

Zacks.com featured highlights include: RentACenter, U.S. Physical Therapy, Cellectar Biosciences, Toro and Zymeworks

by Zacks Equity Research

RentACenter, U.S. Physical Therapy, Cellectar Biosciences, Toro and Zymeworks are highlighted in this Screen of the Week article.

Sanghamitra Saha headshot

Ride on Rising P/E Investing With These 5 Top-Ranked Stocks

by Sanghamitra Saha

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Zymeworks Inc. (ZYME) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -5.93% and -50.03%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Zymeworks Inc. (ZYME) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zymeworks (ZYME) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Zymeworks (ZYME) has been struggling lately, but the selling pressure may be coming to an end soon.

Here's Why Zymeworks Inc. (ZYME) is Poised for a Turnaround After Losing 24.1% in 4 Weeks

by Zacks Equity Research

Zymeworks Inc. (ZYME) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

New Strong Sell Stocks for August 10th

by Zacks Equity Research

THS, ZYME, NTRA, LAWS, and INSW have been added to the Zacks Rank #5 (Strong Sell) List on August 10, 2021

Zymeworks Inc. (ZYME) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -23.58% and -75.61%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Zymeworks Inc. (ZYME) Q2 Earnings Expected to Decline

by Zacks Equity Research

Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.